Compare Trans Genic Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -155.25% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate -155.25% of over the last 5 years
3
Positive results in Mar 26
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,706 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.01
7.15%
0.78
Revenue and Profits:
Net Sales:
3,479 Million
(Quarterly Results - Mar 2026)
Net Profit:
-107 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.33%
0%
-15.33%
6 Months
-26.33%
0%
-26.33%
1 Year
9.95%
0%
9.95%
2 Years
-3.49%
0%
-3.49%
3 Years
-22.73%
0%
-22.73%
4 Years
-41.22%
0%
-41.22%
5 Years
-58.46%
0%
-58.46%
Trans Genic Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.20%
EBIT Growth (5y)
-155.25%
EBIT to Interest (avg)
15.64
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.65
Tax Ratio
53.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.75%
ROE (avg)
10.01%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
-148.28
EV to EBITDA
31.13
EV to Capital Employed
0.77
EV to Sales
0.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.52%
ROE (Latest)
-6.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
3,479.20
3,470.40
0.25%
Operating Profit (PBDIT) excl Other Income
74.20
73.00
1.64%
Interest
9.40
9.90
-5.05%
Exceptional Items
-305.40
-128.80
-137.11%
Consolidate Net Profit
-106.90
-1.30
-8,123.08%
Operating Profit Margin (Excl OI)
9.60%
9.60%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.25% vs 14.65% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -8,123.08% vs -165.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
13,174.40
13,005.10
1.30%
Operating Profit (PBDIT) excl Other Income
293.60
-64.40
555.90%
Interest
45.80
36.60
25.14%
Exceptional Items
-458.40
-373.60
-22.70%
Consolidate Net Profit
-97.50
-1,090.60
91.06%
Operating Profit Margin (Excl OI)
10.50%
-19.60%
3.01%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.30% vs -0.60% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 91.06% vs -27,365.00% in Mar 2025
About Trans Genic Inc. 
Trans Genic Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






